Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R D Johnston

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
European Journal of Cancer Care|August 26, 2010
Living with secondary breast cancer: coping with an uncertain future with unmet needsS R D Johnston
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 3, 2006
Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonistsS R D Johnston
Breast Cancer Research : BCR|January 9, 2009
Integration of endocrine therapy with targeted agentsStephen R D Johnston
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
New strategies in estrogen receptor-positive breast cancerStephen R D Johnston
Idrugs : the Investigational Drugs Journal|June 6, 2003
BMS-214662 (Bristol-Myers Squibb)Stephen R D Johnston
The Lancet. Oncology|March 25, 2014
Can NOAH guide us to improved survival in breast cancer?Stephen R D Johnston
Annals of Palliative Medicine|January 30, 2023
Adjuvant CDK4/6 inhibitors: can they improve clinical outcomes in hormone receptor-positive (HR+) early breast cancer?Stephen R D Johnston
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
The role of chemotherapy and targeted agents in patients with metastatic breast cancerStephen R D Johnston
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Chairperson's introduction: Despite significant advances in the diagnosis and treatment of breast cancer, approximately one third of patients still develop, and subsequently die from metastatic breast diseaseStephen R D Johnston
Breast Cancer Research and Treatment|October 19, 2010
Are we missing the mTOR target in breast cancer?Stephen R D Johnston
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
European Journal of Cancer Care|August 26, 2010
Living with secondary breast cancer: coping with an uncertain future with unmet needsS R D Johnston
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 3, 2006
Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonistsS R D Johnston
Breast Cancer Research : BCR|January 9, 2009
Integration of endocrine therapy with targeted agentsStephen R D Johnston
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
New strategies in estrogen receptor-positive breast cancerStephen R D Johnston
Idrugs : the Investigational Drugs Journal|June 6, 2003
BMS-214662 (Bristol-Myers Squibb)Stephen R D Johnston
The Lancet. Oncology|March 25, 2014
Can NOAH guide us to improved survival in breast cancer?Stephen R D Johnston
Annals of Palliative Medicine|January 30, 2023
Adjuvant CDK4/6 inhibitors: can they improve clinical outcomes in hormone receptor-positive (HR+) early breast cancer?Stephen R D Johnston
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
The role of chemotherapy and targeted agents in patients with metastatic breast cancerStephen R D Johnston
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Chairperson's introduction: Despite significant advances in the diagnosis and treatment of breast cancer, approximately one third of patients still develop, and subsequently die from metastatic breast diseaseStephen R D Johnston
Breast Cancer Research and Treatment|October 19, 2010
Are we missing the mTOR target in breast cancer?Stephen R D Johnston
Pageof 14